Effect evaluation of transcatheter arterial chemoembossment combined with PD1 inhibitor in the treatment of advanced liver cancer

Abstract

Advanced liver cancer is a malignant tumor with rapid progress and poor prognosis, and the effectiveness of traditional treatment methods is limited. The purpose of this study is to evaluate the therapeutic effect of transcatheter arterial chemoembossmen (TACE) combined with PD1 inhibitor in patients with advanced liver cancer. A cohort of patients diagnosed with advanced liver cancer was randomly assigned to either the Combined Treatment Group (CTG) or the Single Treatment Group (STG). The CTG underwent treatment involving TACE in combination with a PD-1 inhibitor, while the STG received conventional therapy. The therapeutic effects of both groups were comprehensively assessed through survival analysis, adverse reaction analysis, and evaluations of quality of life. The CTG exhibited significant advantages in terms of survival rate, with the survival curve indicating a more favorable trend (p < 0.05). Adverse reaction analysis revealed that the incidence of adverse reactions in the CTG was slightly higher than that in the STG, but the difference was statistically significant (p < 0.05). Quality of life assessments indicated superior overall quality of life and physiological function in the CTG, although there was a slight decrement in symptoms compared to the STG. In conclusion, the combined therapy of TACE and PD-1 inhibitor demonstrated notable efficacy in treating advanced liver cancer, leading to a significant improvement in both the survival rate and overall quality of life for patients. Despite the presence of some adverse reactions, the therapeutic advantages of this combination warrant careful consideration. In clinical practice, doctors need to weigh the advantages and disadvantages of combined treatment according to the individual differences and treatment expectations of patients. Future research should further verify the long-term efficacy of this treatment scheme and confirm its position in the treatment of advanced liver cancer through larger-scale clinical trials.